153 related articles for article (PubMed ID: 25511143)
1. Blood flow cytometry in Sézary syndrome: new insights on prognostic relevance and immunophenotypic changes during follow-up.
Novelli M; Fava P; Sarda C; Ponti R; Osella-Abate S; Savoia P; Bergallo M; Lisa F; Fierro MT; Quaglino P
Am J Clin Pathol; 2015 Jan; 143(1):57-69. PubMed ID: 25511143
[TBL] [Abstract][Full Text] [Related]
2. Utility of flow cytometry immunophenotyping and DNA ploidy studies for diagnosis and characterization of blood involvement in CD4+ Sézary's syndrome.
Lima M; Almeida J; dos Anjos Teixeira M; Queiros ML; Santos AH; Fonseca S; Balanzategui A; Justica B; Orfao A
Haematologica; 2003 Aug; 88(8):874-87. PubMed ID: 12935975
[TBL] [Abstract][Full Text] [Related]
3. Immunophenotypic stability of Sézary cells by flow cytometry: usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy.
Vaughan J; Harrington AM; Hari PN; Kroft SH; Olteanu H
Am J Clin Pathol; 2012 Mar; 137(3):403-11. PubMed ID: 22338052
[TBL] [Abstract][Full Text] [Related]
4. Association of change in clinical status and change in the percentage of the CD4+CD26- lymphocyte population in patients with Sézary syndrome.
Introcaso CE; Hess SD; Kamoun M; Ubriani R; Gelfand JM; Rook AH
J Am Acad Dermatol; 2005 Sep; 53(3):428-34. PubMed ID: 16112348
[TBL] [Abstract][Full Text] [Related]
5. Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26- or CD7- CD4+ T-cells.
Lyapichev KA; Bah I; Huen A; Duvic M; Routbort MJ; Wang W; Jorgensen JL; Medeiros LJ; Vega F; Craig FE; Wang SA
Cytometry B Clin Cytom; 2021 Mar; 100(2):183-191. PubMed ID: 32667737
[TBL] [Abstract][Full Text] [Related]
6. Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with Sézary syndrome.
Sokolowska-Wojdylo M; Wenzel J; Gaffal E; Steitz J; Roszkiewicz J; Bieber T; Tüting T
Clin Exp Dermatol; 2005 Nov; 30(6):702-6. PubMed ID: 16197392
[TBL] [Abstract][Full Text] [Related]
7. The usefulness of CD26 in flow cytometric analysis of peripheral blood in Sézary syndrome.
Kelemen K; Guitart J; Kuzel TM; Goolsby CL; Peterson LC
Am J Clin Pathol; 2008 Jan; 129(1):146-56. PubMed ID: 18089499
[TBL] [Abstract][Full Text] [Related]
8. The relevance of the CD4+ CD26- subset in the identification of circulating Sézary cells.
Bernengo MG; Novelli M; Quaglino P; Lisa F; De Matteis A; Savoia P; Cappello N; Fierro MT
Br J Dermatol; 2001 Jan; 144(1):125-35. PubMed ID: 11167693
[TBL] [Abstract][Full Text] [Related]
9. The diagnosis of Sézary syndrome on peripheral blood by flow cytometry requires the use of multiple markers.
Klemke CD; Brade J; Weckesser S; Sachse MM; Booken N; Neumaier M; Goerdt S; Nebe TC
Br J Dermatol; 2008 Sep; 159(4):871-80. PubMed ID: 18652582
[TBL] [Abstract][Full Text] [Related]
10. Simplified flow cytometric assessment in mycosis fungoides and Sézary syndrome.
Hristov AC; Vonderheid EC; Borowitz MJ
Am J Clin Pathol; 2011 Dec; 136(6):944-53. PubMed ID: 22095381
[TBL] [Abstract][Full Text] [Related]
11. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood.
Jones D; Dang NH; Duvic M; Washington LT; Huh YO
Am J Clin Pathol; 2001 Jun; 115(6):885-92. PubMed ID: 11392886
[TBL] [Abstract][Full Text] [Related]
12. CD4(+)CD7(-) T cells compose the dominant T-cell clone in the peripheral blood of patients with Sézary syndrome.
Rappl G; Muche JM; Abken H; Sterry W; Tilgen W; Ugurel S; Reinhold U
J Am Acad Dermatol; 2001 Mar; 44(3):456-61. PubMed ID: 11209115
[TBL] [Abstract][Full Text] [Related]
13. Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker.
Roelens M; de Masson A; Ram-Wolff C; Maki G; Cayuela JM; Marie-Cardine A; Bensussan A; Toubert A; Bagot M; Moins-Teisserenc H
Br J Dermatol; 2020 Jun; 182(6):1415-1422. PubMed ID: 31487384
[TBL] [Abstract][Full Text] [Related]
14. Expression of CD164 on Malignant T cells in Sézary Syndrome.
Guenova E; Ignatova D; Chang YT; Contassot E; Mehra T; Saulite I; Navarini AA; Mitev V; Dummer R; Kazakov DV; French LE; Hoetzenecker W; Cozzio A
Acta Derm Venereol; 2016 May; 96(4):464-7. PubMed ID: 26524186
[TBL] [Abstract][Full Text] [Related]
15. Peripheral blood findings in erythrodermic patients: importance for the differential diagnosis of Sézary syndrome.
Nagler AR; Samimi S; Schaffer A; Vittorio CC; Kim EJ; Rook AH
J Am Acad Dermatol; 2012 Mar; 66(3):503-8. PubMed ID: 22005074
[TBL] [Abstract][Full Text] [Related]
16. [Use of the multiparametric panel CD3/CD4/CD8/CD7/CD26/CD158k in the detection and use of flow cytometry of Sezary cells].
Callet J; Latger-Cannard V; Gérard D; Salignac S; Granel-Brocard F; Campidelli A; Bursztejn AC; Broséus J; Vial JP; Lesesve JF
Ann Biol Clin (Paris); 2021 Jun; 79(3):233-240. PubMed ID: 34165432
[TBL] [Abstract][Full Text] [Related]
17. Skewed expression of activation, differentiation and homing-related antigens in circulating cells from patients with cutaneous T cell lymphoma associated with CD7- T helper lymphocytes expansion.
Scala E; Russo G; Cadoni S; Narducci MG; Girardelli CR; De Pità O; Puddu P
J Invest Dermatol; 1999 Oct; 113(4):622-7. PubMed ID: 10504451
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of genetically defined tumor cells in CD7 as well as CD26 positive and negative circulating T-cell subsets in Sézary syndrome.
Steinhoff M; Schöpp S; Assaf C; Muche M; Beyer M; Sterry W; Lukowsky A
Leuk Res; 2009 Jan; 33(1):88-99. PubMed ID: 18672285
[TBL] [Abstract][Full Text] [Related]
19. Detection of circulating T cells with CD4+CD7- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses.
Harmon CB; Witzig TE; Katzmann JA; Pittelkow MR
J Am Acad Dermatol; 1996 Sep; 35(3 Pt 1):404-10. PubMed ID: 8784277
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Immunophenotypic and Molecular Biomarkers for Sézary Syndrome Using Standard Operating Procedures: A Multicenter Study of 59 Patients.
Boonk SE; Zoutman WH; Marie-Cardine A; van der Fits L; Out-Luiting JJ; Mitchell TJ; Tosi I; Morris SL; Moriarty B; Booken N; Felcht M; Quaglino P; Ponti R; Barberio E; Ram-Wolff C; Jäntti K; Ranki A; Bernengo MG; Klemke CD; Bensussan A; Michel L; Whittaker S; Bagot M; Tensen CP; Willemze R; Vermeer MH
J Invest Dermatol; 2016 Jul; 136(7):1364-1372. PubMed ID: 26930587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
